New hope for mesothelioma? drug targets CD30-Positive tumors
NCT ID NCT03007030
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests brentuximab vedotin (Adcetris) in 55 patients with CD30+ malignant mesothelioma that cannot be removed by surgery. The drug is an antibody-drug conjugate designed to seek out and attack cancer cells carrying the CD30 marker. The main goal is to see if the drug can control the disease—shrink tumors or keep them stable—with a target of at least 50% of patients benefiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brentuximab vedotin (Adcetris)
What this could lead to
If successful, this could offer a new treatment option for patients with CD30+ mesothelioma that cannot be surgically removed.
What could go wrong
This is a small, early-phase trial (55 patients) with no control group. The drug may not shrink tumors or improve survival, and side effects like nerve damage or infusion reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact